Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (June 2021)
23 slides from Inspiremd's investor presentation, Jun 8, 2021
Slide 1: InspireMD: Sustained Embolic Protection
INSPIREM9 Sustained Embolic Protection
Slide 2: Disclaimers
M Disclaimers This presentation contains “forward-looking statements." Such statements may be preceded by the words “intends,” "may," “will,” "plans," “expects,” “anticipates,” "projects," “predicts,” "estimates," "aims," "believes," "hopes," “potential” or similar words. Forward- looking statements
Slide 3: About InspireMD
m= About InspireMD InspireMD is a commercial-stage medical device company focused on stroke prevention in patients with carotid artery disease and treatment of other minimally invasive indications utilizing an integrated embolic protection stent platform. MicroNet™ is a proprietary platform comprise
Slide 4: Our Leadership
m= Our Leadership Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership in Marvin L. Slosman commercialization and international market development Dresden and GEO in both public and privately held companies. He has had senior management roles in a variet
Slide 5: InspireMD Pipeline
InspireMD Pipeline ar Commercial Stage ee The CGuard™ Carotid Stent with Embolic Prevention System SS a Stroke his ‘otection: (EPS) is designed to improve patient safety through sustained =). & CGuard™ EPS embolic protection’? using our MicroNet™ technology. — SS ~~! © i ith Mi ™M ji i ie Myocardium
Slide 6: Endovascular Procedures: Landscape and InspireMD Potential
m Endovascular Procedures: Landscape and InspireMD Potential CEREBRAL CORONARY THORACIC/ PERIPHERAL ANEURYSMS ARTERY ABDOMINAL ARTERIAL DISEASE AORTIC DISEASE ANEURYSMS (PAD) 70% Endo! 77% Endo? 65% Endo? ‘ 81% Endo* 30% Surgical’ , 23% Surgical? 35% 19% Surgical4 Surgical / Other Already have been
Slide 7: Stroke is the Second Biggest Cause of Death Globally
MI Stroke is the Second Biggest Cause of Death Globally An estimated 15 million people suffer from stroke annually! * 6.2 million deaths? 5 million people left permanently disabled’ @ $34 billion associated with stroke management in the US alone® @ 85% of all strokes are ischemic strokes, which resu
Slide 8: The Problem: Risks with Existing Approaches to CAD
m THE PROBLEM: Risks with Existing Approaches to CAD Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks Carotid Endarterectomy (CEA) Carotid Artery Stenting (CAS) Surgical Approach Conventional Approach (Bare Stent) Risk of complications: Risk of complications: + Myoca
Slide 9: The Problem: Risk of Embolism Following Conventional CAS
m THE PROBLEM: Risk of Embolism Following Conventional CAS MRI reveals post-procedural cerebral embolization Pre-Procedure Post-Procedure with Conventional Stent 90% occlusion MRI of a pre-existing white Successful MRI reveals new multiple micro- of the carotid matter infarction opening of the infar
Slide 10: Our Solution: Proprietary MicroNet Technology
m= OUR SOLUTION: Proprietary MicroNet™ Technology New mesh covered stent that offers superior plaque coverage when compared to conventional stent A OU) ays ee Conventional Stent: Bare or dual layer approach, with plaque protrusion risk Stents are covered in Micronet™ INSPIREM9 MicroNet™: an Embolic
Slide 11: Mechanics Translate to Clinical Results
m= Mechanics Translate to Clinical Results 1900p Open cell stent [ TERUMO GORE * Average in lesion at expanded state Musialek, Piotr, MD DPHIL. Mesh-Covered Stents for Carotid Intervention: Rationale, Device Designs, Imaging and Data to Date . Presentation at TCT Congress 2015, San Francisco, Califo
Slide 12: Carotid Solution: Our Well Studied Mesh-Covered Technology
= Carotid Solution: Our Well Studied Mesh-Covered Technology More than 1,500 patients in Clinical Publications and Studies Clinical Result of the Caroti Embolic Prove — ‘rea not ‘Steph ran, Initial Clinical Resules and In Viero Testing. ‘ofthe New CGuard MicroNet-Covered “One Size-Fits-Al" Carotid S
Slide 13: Timeline Growth: From Alternative Stent to New Gold Standard
= Timeline Growth: From Alternative Stent to New Gold Standard YEAR STUDY CGUARD’S STANDING PUBLICATION HIGHLIGHTS (known & anticipated) 2020 IRON-GUARD 2 2021 CGuard-TCAS 2021 IRON-GUARD 2 2021 SIBERIA ONE SIZE-FIT- ALL PARADIGM Extend 2021 Meta-Analysis 2021 Meta-Analysis 2021 OCTOPVS 2022 OPTIMA
Slide 14: CGuard EPS Yields Superior Clinical Outcomes
m= CGuard™ EPS Yields Superior Clinical Outcomes When compared with Conventional Stents and Surgery (CEA), CGuard™ trends Superior 30 Day DSM (Death, Stroke, Myocardial Infarction) 6.00% 5.20% | 5.00% a 4.50% 4.00% 3.00% 2) so0K 1.77% 1.00% 0.00% CGuard™ Conventional Surgery Stents (CEA) 1, IRONGUAR
Slide 15: A Billion Dollar Market
= A Billion Dollar Market Our I Te ed stent: <e CG a WW carotid procedures today are primarily surgical: Stents (CAS): 20% of Market Opportunity ard™ cc pecome the new gol Carotid procedures tomorrow could be mostly minimally invasive with Stents OR s (CAS): of Market 2017 Health Research Internatio
Slide 16: Commercial Footprint
= Commercial Footprint INSPIREM9 Current Markets Registration Work Underway Active selling in 33 countries Over 90% of sales are through channel partners/distributors with move to direct Signed agreement with Chinese distributor. Working toward distribution Exploring expansion opportunities Taiwan,
Slide 17: Growth Pathway to the U.S. Market
= Growth Pathway to the U.S. Market U.S. Market Opportunity* = Size: 192K High Grade Carotid Artery Stenosis (HGCS) interventions in 2017 = Opportunity : At a price of $1,650 per stent, the addressable market is estimated to be approximately $317 million Executing and Funded Approval of FDA PMA for
Slide 18: Our Lead Product, CGuard - Advancing Rapidly
m= Our Lead Product, CGuard™ - Advancing Rapidly 23,000+ Total protected stents sold to date with excellent clinical results INSPIREM9
Slide 19: Our Advancement Roadmap / Milestones
™ Our Advancement Roadmap / Milestones Our Key Value Drivers and Strategic Pathways USA regulatory approval China regulatory advancement "Neuro Guard lounch 2023 ¥ USA IDE tral approved INSPIREMO
Slide 20: Our Robust Intellectual Property Portfolio
= Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP INSPIREM9 Patent Rights USA 15 Pending Rest of World 38 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products
Slide 21: Our Business and Market Development
= Our Business and Market Development Strategic Targets for Merger or Acquisition Synergy ee a a tst‘CSsSe Gohmonafohnron =] Boston. Medtronic stryker ii FS | TA DOUe ~TERUMO Edwards COOK mm CardinatHealth noone ° Telefiex: BARD g " @& BIOTRONIK a ONertat : = SILKROAD> Ojnari GORE, @ \VENUSMEDTECH™
Slide 22: Summary Financials - June 1, 2021
= Summary Financials - June 1%, 2021 NASDAQ Capital Markets NSPR Stock Price $5.31 Average Volume 0.1M Shares Outstanding 7.9M Market Capitalization $41.9M Cash Balance - March 31*, 2021 $44.0M Debt $OoM INSPIREM9
Slide 23: InspireMD
INSPIREM®O NASDAQ = NSPR